<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p71" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_71{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_71{left:341px;bottom:30px;}
#t3_71{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_71{left:377px;bottom:30px;}
#t5_71{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_71{left:540px;bottom:30px;}
#t7_71{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_71{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_71{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_71{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_71{left:285px;bottom:827px;letter-spacing:-0.32px;word-spacing:-0.15px;}
#tc_71{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_71{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_71{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_71{left:1120px;bottom:47px;letter-spacing:0.09px;}
#tg_71{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_71{left:36px;bottom:392px;}
#ti_71{left:46px;bottom:386px;letter-spacing:0.08px;word-spacing:-0.01px;}
#tj_71{left:377px;bottom:386px;letter-spacing:0.12px;}
#tk_71{left:407px;bottom:386px;letter-spacing:0.13px;}
#tl_71{left:481px;bottom:386px;}
#tm_71{left:36px;bottom:376px;}
#tn_71{left:46px;bottom:370px;letter-spacing:0.12px;}
#to_71{left:45px;bottom:353px;letter-spacing:0.12px;}
#tp_71{left:45px;bottom:336px;letter-spacing:0.12px;}
#tq_71{left:45px;bottom:319px;letter-spacing:0.12px;}
#tr_71{left:45px;bottom:302px;letter-spacing:0.12px;}
#ts_71{left:45px;bottom:286px;letter-spacing:0.12px;}
#tt_71{left:45px;bottom:269px;letter-spacing:0.12px;}
#tu_71{left:45px;bottom:252px;letter-spacing:0.11px;word-spacing:0.02px;}
#tv_71{left:45px;bottom:235px;letter-spacing:0.13px;}
#tw_71{left:45px;bottom:218px;letter-spacing:0.11px;word-spacing:0.01px;}
#tx_71{left:45px;bottom:202px;letter-spacing:0.1px;word-spacing:0.02px;}
#ty_71{left:483px;bottom:202px;letter-spacing:0.12px;}
#tz_71{left:45px;bottom:185px;letter-spacing:0.03px;word-spacing:0.11px;}
#t10_71{left:184px;bottom:185px;letter-spacing:0.12px;}
#t11_71{left:45px;bottom:168px;letter-spacing:0.11px;word-spacing:0.02px;}
#t12_71{left:45px;bottom:151px;letter-spacing:0.08px;word-spacing:0.04px;}
#t13_71{left:45px;bottom:134px;letter-spacing:0.12px;word-spacing:-0.06px;}
#t14_71{left:45px;bottom:118px;letter-spacing:0.1px;word-spacing:0.03px;}
#t15_71{left:45px;bottom:101px;letter-spacing:-0.1px;}
#t16_71{left:432px;bottom:778px;letter-spacing:0.39px;word-spacing:-0.22px;}
#t17_71{left:759px;bottom:786px;letter-spacing:-0.12px;}
#t18_71{left:670px;bottom:366px;}
#t19_71{left:681px;bottom:360px;letter-spacing:0.13px;word-spacing:-0.04px;}
#t1a_71{left:679px;bottom:344px;letter-spacing:0.03px;}
#t1b_71{left:744px;bottom:344px;}
#t1c_71{left:670px;bottom:333px;}
#t1d_71{left:681px;bottom:327px;letter-spacing:0.11px;word-spacing:0.02px;}
#t1e_71{left:679px;bottom:310px;letter-spacing:0.12px;word-spacing:0.01px;}
#t1f_71{left:670px;bottom:299px;}
#t1g_71{left:681px;bottom:293px;letter-spacing:0.08px;word-spacing:0.01px;}
#t1h_71{left:679px;bottom:276px;letter-spacing:0.09px;}
#t1i_71{left:679px;bottom:260px;letter-spacing:0.09px;}
#t1j_71{left:679px;bottom:243px;letter-spacing:0.1px;word-spacing:-0.09px;}
#t1k_71{left:670px;bottom:232px;}
#t1l_71{left:681px;bottom:226px;letter-spacing:0.1px;word-spacing:-0.03px;}
#t1m_71{left:679px;bottom:209px;letter-spacing:0.13px;}
#t1n_71{left:679px;bottom:192px;letter-spacing:0.12px;}
#t1o_71{left:679px;bottom:176px;letter-spacing:0.13px;}
#t1p_71{left:670px;bottom:165px;}
#t1q_71{left:681px;bottom:159px;letter-spacing:0.08px;word-spacing:0.04px;}
#t1r_71{left:679px;bottom:142px;letter-spacing:0.12px;}
#t1s_71{left:679px;bottom:125px;letter-spacing:0.13px;}
#t1t_71{left:679px;bottom:108px;letter-spacing:0.13px;}
#t1u_71{left:36px;bottom:748px;letter-spacing:0.41px;word-spacing:-0.25px;}
#t1v_71{left:374px;bottom:755px;}
#t1w_71{left:386px;bottom:748px;letter-spacing:0.36px;word-spacing:-0.18px;}
#t1x_71{left:36px;bottom:729px;letter-spacing:-0.1px;}
#t1y_71{left:41px;bottom:711px;}
#t1z_71{left:58px;bottom:711px;letter-spacing:-0.12px;word-spacing:0.03px;}
#t20_71{left:41px;bottom:693px;}
#t21_71{left:58px;bottom:693px;letter-spacing:-0.09px;}
#t22_71{left:63px;bottom:674px;}
#t23_71{left:76px;bottom:674px;letter-spacing:-0.09px;}
#t24_71{left:547px;bottom:682px;}
#t25_71{left:36px;bottom:642px;letter-spacing:0.3px;word-spacing:-0.13px;}
#t26_71{left:248px;bottom:650px;}
#t27_71{left:36px;bottom:624px;letter-spacing:-0.18px;}
#t28_71{left:36px;bottom:605px;letter-spacing:-0.18px;}
#t29_71{left:711px;bottom:614px;}
#t2a_71{left:716px;bottom:605px;letter-spacing:-0.18px;}
#t2b_71{left:36px;bottom:587px;letter-spacing:-0.18px;}
#t2c_71{left:36px;bottom:569px;letter-spacing:-0.19px;word-spacing:0.01px;}
#t2d_71{left:36px;bottom:550px;letter-spacing:-0.2px;word-spacing:0.02px;}
#t2e_71{left:36px;bottom:532px;letter-spacing:-0.18px;}
#t2f_71{left:36px;bottom:514px;letter-spacing:-0.2px;word-spacing:0.02px;}
#t2g_71{left:36px;bottom:495px;letter-spacing:-0.18px;}
#t2h_71{left:1098px;bottom:503px;}
#t2i_71{left:1111px;bottom:495px;letter-spacing:-0.17px;}
#t2j_71{left:36px;bottom:477px;letter-spacing:-0.18px;}
#t2k_71{left:853px;bottom:485px;letter-spacing:-0.18px;}
#t2l_71{left:876px;bottom:477px;letter-spacing:-0.17px;}
#t2m_71{left:36px;bottom:459px;letter-spacing:-0.17px;}
#t2n_71{left:36px;bottom:440px;letter-spacing:-0.18px;}
#t2o_71{left:36px;bottom:422px;letter-spacing:-0.18px;}
#t2p_71{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_71{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_71{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_71{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_71{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_71{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_71{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_71{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_71{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s8_71{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_71{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sa_71{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_71{font-size:17px;font-family:Webdings_k6;color:#000;}
.sc_71{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.sd_71{font-size:10px;font-family:Arial-BoldMT_5te;color:#000;}
.se_71{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sf_71{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts71" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg71Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg71" style="-webkit-user-select: none;"><object width="1210" height="935" data="71/71.svg" type="image/svg+xml" id="pdf71" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_71" class="t s0_71">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_71" class="t s1_71">® </span>
<span id="t3_71" class="t s0_71">(NCCN </span>
<span id="t4_71" class="t s1_71">® </span>
<span id="t5_71" class="t s0_71">), All rights reserved. NCCN Guidelines </span>
<span id="t6_71" class="t s1_71">® </span>
<span id="t7_71" class="t s0_71">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_71" class="t s2_71">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_71" class="t s2_71">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_71" class="t s3_71">NCCN Guidelines Version 4.2024 </span>
<span id="tb_71" class="t s3_71">Very Advanced Head and Neck Cancer </span>
<span id="tc_71" class="t s4_71">NCCN Guidelines Index </span>
<span id="td_71" class="t s4_71">Table of Contents </span>
<span id="te_71" class="t s4_71">Discussion </span>
<span id="tf_71" class="t s5_71">ADV-A </span>
<span id="tg_71" class="t s5_71">1 OF 2 </span>
<span id="th_71" class="t s6_71">1 </span>
<span id="ti_71" class="t s7_71">See Principles of Radiation Techniques (RAD-A) </span><span id="tj_71" class="t s8_71">and </span><span id="tk_71" class="t s7_71">Discussion</span><span id="tl_71" class="t s8_71">. </span>
<span id="tm_71" class="t s6_71">2 </span>
<span id="tn_71" class="t s8_71">In general, the reirradiated population of patients with head and neck cancer described </span>
<span id="to_71" class="t s8_71">in current literature represents a diverse but highly selected group of patients treated </span>
<span id="tp_71" class="t s8_71">in centers where there is a high level of expertise and systems in place for managing </span>
<span id="tq_71" class="t s8_71">acute and long-term toxicities. When the goal of treatment is curative and surgery is </span>
<span id="tr_71" class="t s8_71">not an option, reirradiation strategies can be considered for patients who: develop </span>
<span id="ts_71" class="t s9_71">locoregional failures or second primaries at ≥6 months after the initial radiotherapy; can </span>
<span id="tt_71" class="t s8_71">receive additional doses of radiotherapy of at least 60 Gy; and can tolerate concurrent </span>
<span id="tu_71" class="t s9_71">chemotherapy. Organs at risk (OARs) for toxicity should be carefully analyzed through </span>
<span id="tv_71" class="t s8_71">review of dose-volume histograms, and consideration for acceptable doses should be </span>
<span id="tw_71" class="t s8_71">made on the basis of time interval since original radiotherapy, anticipated volumes to be </span>
<span id="tx_71" class="t s8_71">included, and patient's life expectancy. For reirradiation dosing, s</span><span id="ty_71" class="t s7_71">ee Principles of Radiation </span>
<span id="tz_71" class="t s7_71">Techniques (RAD-A)</span><span id="t10_71" class="t s8_71">. Proton therapy can be considered when normal tissue constraints </span>
<span id="t11_71" class="t s8_71">cannot be met by photon-based therapy, or when photon-based therapy causes </span>
<span id="t12_71" class="t s8_71">compromise of standard radiation dosing to tumor or postoperative volumes. (Takiar V, </span>
<span id="t13_71" class="t s8_71">Garden AS, Ma D, et al. Reirradiation of head and neck cancers with intensity modulated </span>
<span id="t14_71" class="t s8_71">radiation therapy: Outcomes and analyses. Int J Radiat Oncol Biol Phys 2016;95:1117- </span>
<span id="t15_71" class="t s8_71">1131). </span>
<span id="t16_71" class="t s5_71">PRINCIPLES OF RADIATION THERAPY </span>
<span id="t17_71" class="t sa_71">1,2 </span>
<span id="t18_71" class="t s6_71">3 </span>
<span id="t19_71" class="t s7_71">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers </span>
<span id="t1a_71" class="t s7_71">(SYST-A)</span><span id="t1b_71" class="t s8_71">. </span>
<span id="t1c_71" class="t s6_71">4 </span>
<span id="t1d_71" class="t s8_71">Suggest 44–50 Gy in 3D-CRT and sequentially planned IMRT or 54–63 </span>
<span id="t1e_71" class="t s8_71">Gy with IMRT dose painting technique (dependent on dose per fraction). </span>
<span id="t1f_71" class="t s6_71">5 </span>
<span id="t1g_71" class="t s9_71">RTOG 0522: a randomized phase III trial of concurrent accelerated </span>
<span id="t1h_71" class="t s8_71">radiation and cisplatin versus concurrent accelerated radiation, cisplatin, </span>
<span id="t1i_71" class="t s8_71">and cetuximab (followed by surgery for selected patients) for stage III and </span>
<span id="t1j_71" class="t s8_71">IV head and neck carcinomas. Clin Adv Hematol Oncol 2007;5:79-81. </span>
<span id="t1k_71" class="t s6_71">6 </span>
<span id="t1l_71" class="t s8_71">Ang K, Zhang Q, Wheeler RH, et al. A phase III trial (RTOG 0129) of </span>
<span id="t1m_71" class="t s8_71">two radiation-cisplatin regimens for head and neck carcinomas (HNC): </span>
<span id="t1n_71" class="t s8_71">Impact of radiation and cisplatin intensity on outcome [abstract]. J Clin </span>
<span id="t1o_71" class="t s8_71">Oncol 2010;28(suppl 15):Abstract 5507. </span>
<span id="t1p_71" class="t s6_71">7 </span>
<span id="t1q_71" class="t s8_71">Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus </span>
<span id="t1r_71" class="t s8_71">acceleration of radiotherapy with or without concomitant chemotherapy in </span>
<span id="t1s_71" class="t s8_71">locally advanced head and neck carcinoma (GORTEC 99-02): an open- </span>
<span id="t1t_71" class="t s8_71">label phase 3 randomised trial. Lancet Oncol 2012;13:145-153. </span>
<span id="t1u_71" class="t s5_71">CONCURRENT SYSTEMIC THERAPY/RT </span>
<span id="t1v_71" class="t sa_71">3 </span>
<span id="t1w_71" class="t s5_71">(PREFERRED FOR PATIENTS ELIGIBLE FOR CHEMOTHERAPY): </span>
<span id="t1x_71" class="t s5_71">• PTV </span>
<span id="t1y_71" class="t sb_71"></span><span id="t1z_71" class="t s5_71">High risk: Typically 70 Gy (2.0 Gy/fraction) </span>
<span id="t20_71" class="t sb_71"></span><span id="t21_71" class="t s5_71">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t22_71" class="t sc_71">◊ </span><span id="t23_71" class="t s5_71">44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t24_71" class="t sa_71">4 </span>
<span id="t25_71" class="t s5_71">SYSTEMIC THERAPY/RT: </span>
<span id="t26_71" class="t sa_71">3 </span>
<span id="t27_71" class="t s5_71">Based on published data, concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical </span>
<span id="t28_71" class="t s5_71">dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m </span>
<span id="t29_71" class="t sd_71">2 </span>
<span id="t2a_71" class="t s5_71">; 2–3 cycles of chemotherapy are used depending </span>
<span id="t2b_71" class="t s5_71">on the radiation fractionation scheme (RTOG 0129) (Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with </span>
<span id="t2c_71" class="t s5_71">oropharyngeal cancer. N Engl J Med 2010;363:24-35). When carboplatin and 5-FU are used, then the recommended regimen is standard </span>
<span id="t2d_71" class="t se_71" data-mappings='[[67,"ff"]]'>fractionation plus 3 cycles of chemotherapy [Bourhis J, Sire C, Graﬀ P, et al. Concomitant chemoradiotherapy versus acceleration of </span>
<span id="t2e_71" class="t s5_71">radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label </span>
<span id="t2f_71" class="t s5_71">phase 3 randomised trial. Lancet Oncol 2012;13:145-53]. Other fraction sizes (eg, 1.8 Gy, conventional), multiagent chemotherapy, other dosing </span>
<span id="t2g_71" class="t se_71" data-mappings='[[72,"ffi"]]'>schedules of cisplatin, or altered fractionation with chemotherapy are eﬃcacious, and there is no consensus on the optimal approach. </span>
<span id="t2h_71" class="t sa_71">5 </span>
<span id="t2i_71" class="t s5_71">Data </span>
<span id="t2j_71" class="t se_71" data-mappings='[[50,"ff"],[64,"ffi"]]'>indicate that accelerated fractionation does not oﬀer improved eﬃcacy over conventional fractionation. </span>
<span id="t2k_71" class="t sa_71">6,7 </span>
<span id="t2l_71" class="t s5_71">In general, the use of concurrent </span>
<span id="t2m_71" class="t s5_71">systemic therapy/RT carries a high toxicity burden; multiagent chemotherapy will likely further increase the toxicity burden. For any systemic </span>
<span id="t2n_71" class="t se_71" data-mappings='[[86,"fi"]]'>therapy/RT approach, close attention should be paid to published reports for the speciﬁc chemotherapy agent, dose, and schedule of </span>
<span id="t2o_71" class="t s5_71">administration. Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care. </span>
<span id="t2p_71" class="t sf_71">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
